Meeting the Challenges of IBD Management in the Era of COVID-19
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Click Here to Manage Email Alerts
OverviewActivity Release Date: 01/04/2022
Activity Expiration Date: 01/04/2023
Estimated Time to Complete Activity: 0.5 hours
Provider StatementProvided by RMEI Medical Education, LLC.
Target AudienceThis activity is intended for gastroenterology clinicians (MD/DO/NP/PA) and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).
Activity DescriptionWe have surveyed inflammatory bowel disease (IBD) providers around the country to find what cases they have struggled with when their patients with IBD concurrently developed COVID-19. In this activity, an IBD expert panel has been convened to discuss cases submitted by these physicians and answer questions such as, do biologics need to be interrupted? Do mRNA vaccines work when a patient is on a biologic? Do the COVID-19 vaccines cause IBD to flare? The panel takes on these timely questions and introduces you to a novel clinical decision support tool that you can access right now to help you assess your patients’ IBD complication risk and predict their response to biologics. The panel directly demonstrates how to utilize this free tool to manage IBD in these challenging cases, how your colleagues have been using it already, and how you can take advantage of it too.
Educational ObjectivesUpon completion of this activity, participants should be better able to:
- Stratify patients with inflammatory bowel disease (IBD) by disease severity and complication risk using predictive decision support tools
- Implement personalized approaches to biologic therapies for patients with IBD based on probability of response to treatment
- Identify patients with IBD at high risk of complications who may require treat-to-target monitoring or combination therapy
Parambir Dulai, MD (Chair)
UC San Diego School of Medicine
La Jolla, CA
Gursimran Singh Kochhar, MD, FACP, CNSC
Associate Chief Division, Gastroenterology, Hepatology & Nutrition
Medical Director, Endoscopic Innovations AHN
Assistant Professor of Medicine, Drexel University
Interventional IBD & Therapeutic Endoscopy
Allegheny Health Network
Ryan Ungaro, MD, MS
The Susan and Leonard Feinstein IBD Center
Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosure of Financial RelationshipsRMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
FacultyParambir Dulai, MD, has relevant financial relationships with AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Takeda (Consultant). Gursimran Singh Kochhar, MD, has a relevant financial relationship with AbbVie (Grant/Research Support paid to Allegheny Health Network). Ryan C. Ungaro, MD, has relevant financial relationships with AbbVie, Bristol Myers Squibb, Janssen, Pfizer (Consultant); AbbVie, Boehringer Ingelheim, Pfizer (Grant/Research Support); Janssen, Pfizer, Takeda (Speaker/Speaker’s Bureau). All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies. Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Accreditation StatementIn support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit DesignationPhysician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
How to Participate in This Activity and Obtain CME CreditIn order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at firstname.lastname@example.org. Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
COPYRIGHT © 2021. RMEI MEDICAL EDUCATION, LLC. ALL RIGHTS RESERVED
E-mail RMEI at email@example.com